Researchers to test drug candidate for eumycetoma

September 10, 2015

The Drugs for Neglected Diseases initiative (DNDi) and the Japanese pharmaceutical company Eisai Co., Ltd. have signed an agreement to proceed with the clinical development of Eisai's anti-fungal drug fosravuconazole for the potential new treatment of eumycetoma, a fungal form of mycetoma, one of the world's most neglected diseases.

Most probably transmitted through pricks to the skin by walking barefoot, eumycetoma is a that affects people in tropical and , in particular across Africa, with the highest burden found in Sudan. The fungus penetrates the skin and causes massive tumour-like lesions that lead to serious disability, grave socioeconomic consequences, and .

There is only one current treatment option, which is expensive, toxic, and only cures about 30% of patients even after twelve months of treatment. Those who aren't cured are at risk of repeated amputations as the infection spreads throughout the body.

Fosravuconazole, an azole-class antifungal drug discovered by Eisai, has shown in vitro and in vivo to have strong antifungal activities against eumycetoma. Under the terms of the agreement, DNDi and partners will be conducting the to assess safety and efficacy of fosravuconazole in patients with the disease, while Eisai provides DNDi with its scientific expertise as well as a supply of the drug for the clinical studies. Eisai also has the option to become DNDi's industrial partner to manufacture, register, and make available fosravuconazole at an affordable price to the public sector in endemic areas.

'We are very excited about the possibility of a new treatment against this terrible and neglected condition', said Dr Nathalie Strub-Wourgaft, Medical Director of DNDi. 'Eumycetoma patients have received little attention and virtually no research and development has addressed their needs.'

There are major knowledge gaps about mycetoma in general, including about its transmission, prevalence, route of infection, and susceptibility. The disease was only recently added to the World Health Organization (WHO) list of neglected tropical diseases in 2013, under 'other neglected conditions'.

The video will load shortly.
Mycetoma is a chronic, destructive morbid inflammatory disease particularly endemic in Sudan as well as in regional neighbors Chad, Niger, Nigeria, Ethiopia, Somalia, parts of Saudi Arabia and Yemen. For many years, the available treatments for mycetoma have only been 25-27 percent effective. However there is hope as DNDi and Japanese pharmaceutical company Eisai Co. Ltd. proceed with the clinical development of Eisai’s anti-fungal drug fosravuconazole for the potential new treatment of eumycetoma, a fungal form of mycetoma. A study will be conducted at the Mycetoma Research Centre to determine the safety and efficacy of the drug. Credit: DNDi & Mycetoma Research Centre

'Mycetoma is a serious global health issue affecting mostly young adults in developing countries, particularly those of low socioeconomic status and manual workers such as agriculturalists, labourers and herdsmen', said Takashi Owa, Ph.D., Chief Innovation Officer, Eisai Co., Ltd. 'As a human health care company, we are committed to developing a new treatment for this horrendous disease, thereby contributing to the lives of people in endemic areas.'

Fosravuconazole will be investigated in a randomized controlled trial to study the efficacy of the drug compared to an existing therapy in moderate eumycetoma cases. This study is scheduled to start in 2016, and will be conducted by DNDi in collaboration with the Mycetoma Research Center (MRC) of the University of Khartoum, Sudan.

Explore further: Drugs for Neglected Diseases initiative unveils new plan for neglected patients

Related Stories

Drugs for Neglected Diseases initiative unveils new plan for neglected patients

September 8, 2015
After having built the world's largest drug development pipeline for the most neglected diseases, the Drugs for Neglected Diseases initiative (DNDi) has unveiled plans for a more flexible, dynamic portfolio approach, integrating ...

Clinical trial for first oral drug candidate specifically developed for sleeping sickness

September 8, 2015
The Drugs for Neglected Diseases initiative (DNDi) has announced today at the 9th European Congress on Tropical Medicine and International Health (ECTMIH) in Basel, Switzerland, the successful completion of Phase I human ...

Drug trial for top parasitic killer of the Americas: Mixed results, new evidence to improve therapy

November 14, 2013
According to results of the first-ever Phase 2 clinical trial in Bolivia, conducted by the Drugs for Neglected Diseases initiative (DNDi), the experimental drug candidate E1224 showed good safety and was effective at clearing ...

Open access initiative reveals drug hits for deadly neglected tropical diseases

November 13, 2012
The Drugs for Neglected Diseases initiative (DNDi) and Medicines for Malaria Venture (MMV) announce today the identification of three chemical series targeting the treatment of deadly neglected tropical diseases (NTDs), through ...

Fulbright scholar tracks puzzling disease that strikes from soils, thorns

February 3, 2015
Mycetoma, a mysterious illness largely unknown in developed nations, has wreaked havoc on the health of farmers, herdsmen, children and others in close contact with the land in tropical and subtropical regions of our planet.

Bayer and DNDi sign agreement to develop an oral treatment for river blindness

December 9, 2014
Bayer HealthCare and the Drugs for Neglected Diseases initiative (DNDi) have signed an agreement under which Bayer will provide the active ingredient emodepside to support DNDi in its effort to develop a new oral drug to ...

Recommended for you

Data revealed under FOI shows benefits of multiple sclerosis drug currently blocked by regulators

August 17, 2017
A drug that is blocked by the EU regulatory system has now been found to improve the quality of life of people with multiple sclerosis (MS), according to a study by Queen Mary University of London (QMUL).

Opioids overused in migraine treatment, regardless of race, study finds

August 17, 2017
African-Americans are more likely to experience debilitating migraine headaches than whites, but a new study probing the issue found no evidence of racial disparities in treatment practices.

Finding better ways to reduce serious drug side effects

August 14, 2017
Many of the medicines we depend on to treat disease—and even to save our lives—pose potentially serious risks along with their benefits. Data from the U.S. Centers for Disease Control and Prevention indicate that about ...

Ultrasound-triggered liposomes for on-demand, local anesthesia

August 10, 2017
Researchers at Boston Children's Hospital have found a new way to non-invasively relieve pain at local sites in the body; such systems could one day improve pain management by replacing addictive opioids and short-lasting ...

Independent pharmacies and online coupons help patients save money on drugs

August 8, 2017
Uninsured patients or those with limited prescription drug coverage can save significant money by buying their drugs at independent pharmacies instead of big box, grocery or chain drug stores and by using discount coupons, ...

New study generates more accurate estimates of state opioid and heroin fatalities

August 7, 2017
Although opioid and heroin deaths have been rising dramatically in the U.S., the magnitude of the epidemic varies from state to state, as does the relative proportion of opioid vs heroin poisonings. Further complicating the ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.